BTK inhibitors can regulate the functions of various immune cells that are crucial to innate and adaptive immune responses.

Guangzhou Gloria Biosciences has announced that Zimberelimab injection (YuTuo®, GLS-010), has received marketing approval from the China NMPA.

This article summarized the latest R&D progress of Dicloxacillin sodium, the Mechanism of Action for Dicloxacillin sodium, and the drug target R&D trends for Dicloxacillin sodium.

BRD4 inhibitors target BRD4 for inhibition, which hold tremendous value in anti-cancer and anti-inflammatory sectors, as well as many other fields.

SpliSense declared the successful completion of a Phase 1 clinical trial for SPL84.

This article summarized the latest R&D progress of Cinacalcet hydrochloride, the Mechanism of Action for Cinacalcet hydrochloride, and the drug target R&D trends for Cinacalcet hydrochloride.

Verismo Therapeutics, a clinical-stage company specializing in CAR-T therapies, has initiated the dosing of the first patient in their STAR-101 clinical trial.

This article summarized the latest R&D progress of Vardenafil hydrochloride, the Mechanism of Action for Vardenafil hydrochloride, and the drug target R&D trends for Vardenafil hydrochloride.

BET (Bromodomain and Extra-Terminal) proteins play a crucial role in the regulation of gene expression in the human body.

Viking Therapeutics, Inc. has recently commenced a Phase 2 clinical evaluation of VK2735.

This article summarized the latest R&D progress of Valrubicin, the Mechanism of Action for Valrubicin, and the drug target R&D trends for Valrubicin.

Atamyo Therapeutics proclaimed that the FDA has given the green light for its ATA-100 IND application to advance into a Phase 1b/2b clinical study.